← All compounds

Thymosin Alpha-1

5mg vial
A$ 120Rp 1.350.000
Bulk buy pricing
3–5 vials
A$ 111
Save ~9%
6–9 vials
A$ 102
Save ~13%
10+ vials
A$ 93
Save ~22%

A compound produced naturally by the thymus gland, studied for immune regulation and immune system restoration. Research supports its use in reducing inflammatory signalling, enhancing the immune response to infection and chronic illness, and supporting recovery in clients whose immune function has been suppressed by illness, overtraining, or long-term stress.


Compound overview

What it is

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally secreted by the thymus gland. It modulates T-cell maturation and function — increasing CD4+ helper T cells, CD8+ cytotoxic T cells, and NK (natural killer) cell activity. It also upregulates MHC class II antigen presentation on dendritic cells, enhancing the adaptive immune response. Simultaneously, it suppresses excessive or dysregulated inflammatory signalling. The net effect is a more capable, balanced immune system — not simply a stimulated one.

Immune competence improves. In chronically ill or immunocompromised clients, T-cell counts and function normalise. Infection susceptibility and severity decline. Chronic inflammatory states — where the immune system is persistently activated but not resolving — tend to moderate. Recovery from illness or intense physical stress accelerates.

Studied outcomes
  • Enhanced T-cell function and counts in immunocompromised patients
  • Improved outcomes in chronic hepatitis B and C studies
  • Adjunctive benefit in sepsis and critical illness immune protocols
  • Reduced infection rates in clinical immunology settings
  • Regulation of inflammatory cytokine profiles — reducing TNF-α and IL-6

Suitability

Who it's for

  • Immune restoration after illness, long COVID, chemotherapy, or chronic infection
  • Recurrent infections — respiratory, viral, or bacterial
  • Chronic inflammation and autoimmune-adjacent dysregulation
  • Athletes experiencing immune suppression from overtraining
Who should avoid it
  • Active autoimmune disease on immunosuppressive therapy — immune upregulation may worsen condition
  • Pregnancy (insufficient data)
  • Organ transplant recipients on immunosuppression

Dosing guidance

Protocol guidance

Dose
1.6mg per injection
Frequency
Twice weekly for standard protocols; daily for acute infection support
Cycle length
4–12 weeks
Route
Subcutaneous injection
Timing
No strict timing

Safety

Contraindications & cautions

  • Do not use in active autoimmune disease on immunosuppression — immune upregulation is the mechanism
  • Well-tolerated in extensive clinical studies across decades of use
  • In HIV or cancer protocols, co-ordinate with treating physician

Stacking

Pairs well with

Combined antioxidant and immune support for post-illness recovery

KPV reduces cytokine load; Thymosin Alpha-1 restores T-cell function — complementary immune balance

Innate immune support (LL-37) + adaptive immune restoration (Thymosin Alpha-1)


Evidence base

Research

Goldstein & Goldstein (2009) — Thymosin Alpha-1 mechanisms reviewMatteucci et al. (2001) — Tα1 in chronic hepatitis

Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.